Cargando…

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-generation potent and selective inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannelli, Francesco, Crupi, Francesca, Zanotti, Roberta, Pagano, Livio, Rapezzi, Davide, Tanasi, Ilaria, Criscuolo, Marianna, Bonifacio, Massimiliano, Fresa, Alberto, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623899/ https://www.ncbi.nlm.nih.gov/pubmed/37929078 http://dx.doi.org/10.1177/20406207231205643

Ejemplares similares

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Bone Marrow Mastocytosis: A Diagnostic Challenge
por: Zanotti, Roberta, et al.
Publicado: (2021)

Mastocytosis: One Word for Different Diseases
por: Criscuolo, Marianna, et al.
Publicado: (2018)

A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network
por: Zanotti, Roberta, et al.
Publicado: (2021)

Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis
por: Cavazos, Karla, et al.
Publicado: (2022)

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021)

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
por: DeAngelo, Daniel J., et al.
Publicado: (2021)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Validation of the Mayo alliance prognostic system for mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2019)

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

PB2059: SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT
por: Saha, C., et al.
Publicado: (2022)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022)

Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India
por: Verma, Saurav, et al.
Publicado: (2021)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
por: Gotlib, Jason, et al.
Publicado: (2023)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
por: Venkatakrishnan, Ajit, et al.
Publicado: (2022)

Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
por: Crupi, Francesca, et al.
Publicado: (2022)

Avapritinib-induced photo-aggravated cutaneous reaction
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis
por: Bonifacio, Massimiliano, et al.
Publicado: (2017)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Palpable purpuric eruption mimicking vasculitis following avapritinib
por: Mohammed, Taha Osman, et al.
Publicado: (2022)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
por: Nguyen, Hanna, et al.
Publicado: (2021)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021)

Communication, Counseling and Compassionate Care: The least explored and challenging Palliative Care approaches among Primary Care Physicians - Clinical Case series of Oral Potentially malignant disorders in Tamil Nadu
por: Raman, Praveena
Publicado: (2021)

Editorial: Compassion and compassionate leadership in the workplace
por: Benevene, Paula, et al.
Publicado: (2022)

The economic impact of compassionate use of medicines
por: Jommi, Claudio, et al.
Publicado: (2021)

Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis
por: Mannelli, Francesco
Publicado: (2020)

INFIX/EXFIX: Innovation managing pelvic fractures in difficult scenarios
por: Bagga, R, et al.
Publicado: (2019)

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
por: Ye, Shuai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i4unkp7m96eq3v670am5oabe2g